Gilead Sciences Inc.’s main purpose for its presentation at the JP Morgan Healthcare Conference Jan. 9 seemed to be a show of strength, with CEO John Milligan discussing remaining opportunities in hepatitis C and HIV and the ways his company might study its three mid-stage non-alcoholic steatohepatitis (NASH) candidates together as combination therapy.
With sales of its blockbuster HCV franchise slowing, stakeholders have looked to Gilead for signals as to how it might...








